Travere Therapeutics
TVTX
122 hedge funds and large institutions have $874M invested in Travere Therapeutics in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 54 increasing their positions, 38 reducing their positions, and 25 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 38
2.05% more ownership
Funds ownership: 102.95% → 105.01% (+2.1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less funds holding
Funds holding: 131 → 122 (-9)
9% less capital invested
Capital invested by funds: $965M → $874M (-$90.7M)
28% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 25
82% less call options, than puts
Call options by funds: $8.56M | Put options by funds: $48M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$19.8M |
| 2 |
PA
Perceptive Advisors
New York
|
+$14.2M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$14M |
| 4 |
Millennium Management
New York
|
+$6.59M |
| 5 |
BlackRock
New York
|
+$6.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$13.4M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$11.3M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$7.22M |
| 4 |
SCM
Scopia Capital Management
New York
|
-$6.52M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$4.64M |
TVTX Hedge Fund Activity: Q2 2019 in Review
122 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q2 2019, worth a combined $874M — down 9.4% from $965M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of TVTX and 18 opened new positions — a net loss of 7 holders — while 38 trimmed existing stakes and 54 added.
The largest buyer was Great Point Partners, opening a new position worth an estimated $19.8M. The largest seller was Jennison Associates, exiting entirely with an estimated $13.4M sold.
- 122 institutional investors held Travere Therapeutics (TVTX) as of Q2 2019, down from 131 in Q1 2019.
- Funds reported $874M of Travere Therapeutics stock for Q2 2019, down 9.4% quarter-over-quarter.
- 18 funds opened new Travere Therapeutics positions in Q2 2019 and 25 closed out, a net change of -7 holders.
- The largest Travere Therapeutics buyer in Q2 2019 was Great Point Partners, an estimated $19.8M added.
- The largest Travere Therapeutics seller in Q2 2019 was Jennison Associates, an estimated $13.4M sold.
Based on aggregated 13F filings for Q2 2019.